FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095911292> ?p ?o ?g. }

• W2095911292 endingPage "774" @default.
• W2095911292 startingPage "770" @default.
• W2095911292 abstract "In 2004, we reported the short-term results of a multicentric, phase 2 study of imatinib 400 mg daily and pegylated interferon-alpha in the treatment of 76 early chronic phase Philadelphia-positive chronic myeloid leukemia patients. In this report, we update the results with an observation time of five years. After two years of treatment, all but 10 patients (13%) had discontinued pegylated interferon-alpha. The complete cytogenetic response rate at five years was 87%, and 94% of complete cytogenetic responders maintained the complete cytogenetic response after five years. All but one complete cytogenetic response also achieved a major molecular response. These data confirm the excellent response to imatinib front-line and the stability of the complete cytogenetic response. Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance." @default.
• W2095911292 created "2016-06-24" @default.
• W2095911292 creator A5000866482 @default.
• W2095911292 creator A5002133396 @default.
• W2095911292 creator A5019949455 @default.
• W2095911292 creator A5020333760 @default.
• W2095911292 creator A5031714115 @default.
• W2095911292 creator A5037270007 @default.
• W2095911292 creator A5044224344 @default.
• W2095911292 creator A5048224601 @default.
• W2095911292 creator A5057084037 @default.
• W2095911292 creator A5060457186 @default.
• W2095911292 creator A5063427645 @default.
• W2095911292 creator A5067954471 @default.
• W2095911292 creator A5070777479 @default.
• W2095911292 creator A5073761054 @default.
• W2095911292 creator A5078260568 @default.
• W2095911292 creator A5078872812 @default.
• W2095911292 creator A5089760320 @default.
• W2095911292 date "2008-05-01" @default.
• W2095911292 modified "2023-09-28" @default.
• W2095911292 title "Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome" @default.
• W2095911292 cites W1799579309 @default.
• W2095911292 cites W1979300931 @default.
• W2095911292 cites W1991247976 @default.
• W2095911292 cites W2016086822 @default.
• W2095911292 cites W2028959752 @default.
• W2095911292 cites W2036862498 @default.
• W2095911292 cites W2063599575 @default.
• W2095911292 cites W2079517811 @default.
• W2095911292 cites W2097255369 @default.
• W2095911292 cites W2103974518 @default.
• W2095911292 cites W2107268345 @default.
• W2095911292 cites W2120033838 @default.
• W2095911292 cites W2131656137 @default.
• W2095911292 cites W2142969636 @default.
• W2095911292 cites W2148743957 @default.
• W2095911292 cites W2151486690 @default.
• W2095911292 cites W2157743993 @default.
• W2095911292 cites W2169452890 @default.
• W2095911292 cites W2171722798 @default.
• W2095911292 cites W2244169068 @default.
• W2095911292 cites W2532234056 @default.
• W2095911292 cites W2562310961 @default.
• W2095911292 cites W2596224382 @default.
• W2095911292 doi "https://doi.org/10.3324/haematol.12265" @default.
• W2095911292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18367490" @default.
• W2095911292 hasPublicationYear "2008" @default.
• W2095911292 type Work @default.
• W2095911292 sameAs 2095911292 @default.
• W2095911292 citedByCount "54" @default.
• W2095911292 countsByYear W20959112922012 @default.
• W2095911292 countsByYear W20959112922013 @default.
• W2095911292 countsByYear W20959112922014 @default.
• W2095911292 countsByYear W20959112922015 @default.
• W2095911292 countsByYear W20959112922016 @default.
• W2095911292 countsByYear W20959112922017 @default.
• W2095911292 countsByYear W20959112922019 @default.
• W2095911292 countsByYear W20959112922021 @default.
• W2095911292 countsByYear W20959112922023 @default.
• W2095911292 crossrefType "journal-article" @default.
• W2095911292 hasAuthorship W2095911292A5000866482 @default.
• W2095911292 hasAuthorship W2095911292A5002133396 @default.
• W2095911292 hasAuthorship W2095911292A5019949455 @default.
• W2095911292 hasAuthorship W2095911292A5020333760 @default.
• W2095911292 hasAuthorship W2095911292A5031714115 @default.
• W2095911292 hasAuthorship W2095911292A5037270007 @default.
• W2095911292 hasAuthorship W2095911292A5044224344 @default.
• W2095911292 hasAuthorship W2095911292A5048224601 @default.
• W2095911292 hasAuthorship W2095911292A5057084037 @default.
• W2095911292 hasAuthorship W2095911292A5060457186 @default.
• W2095911292 hasAuthorship W2095911292A5063427645 @default.
• W2095911292 hasAuthorship W2095911292A5067954471 @default.
• W2095911292 hasAuthorship W2095911292A5070777479 @default.
• W2095911292 hasAuthorship W2095911292A5073761054 @default.
• W2095911292 hasAuthorship W2095911292A5078260568 @default.
• W2095911292 hasAuthorship W2095911292A5078872812 @default.
• W2095911292 hasAuthorship W2095911292A5089760320 @default.
• W2095911292 hasBestOaLocation W20959112921 @default.
• W2095911292 hasConcept C104317684 @default.
• W2095911292 hasConcept C126322002 @default.
• W2095911292 hasConcept C138626823 @default.
• W2095911292 hasConcept C143998085 @default.
• W2095911292 hasConcept C17744445 @default.
• W2095911292 hasConcept C199539241 @default.
• W2095911292 hasConcept C203014093 @default.
• W2095911292 hasConcept C2776178377 @default.
• W2095911292 hasConcept C2776694085 @default.
• W2095911292 hasConcept C2777583451 @default.
• W2095911292 hasConcept C2778729363 @default.
• W2095911292 hasConcept C2778904597 @default.
• W2095911292 hasConcept C2781228144 @default.
• W2095911292 hasConcept C2781403576 @default.
• W2095911292 hasConcept C2909179924 @default.
• W2095911292 hasConcept C3019096185 @default.
• W2095911292 hasConcept C3019892230 @default.
• W2095911292 hasConcept C55493867 @default.
• W2095911292 hasConcept C71924100 @default.

• next